To investigate cell morphology, aggrecan expression, and type I, II, III and X collagen expression in chondrocytes from adults with Kashin-Beck disease or osteoarthritis (OA). METHODS: Samples of knee articular cartilage were taken during surgery; cartilage samples obtained from fresh cadavers without arthritic disease were used as controls. Samples were digested with collagenase; isolated chondrocytes were cultured in monolayers. Aggrecan was detected by toluidine blue staining; collagen and aggrecan protein levels were evaluated by immuno cytochemistry and immunofluorescence staining. RESULTS: Samples were obtained from six participants per group. Aggrecan and type II collagen levels in chondrocytes from patients were significantly lower than those from controls, but levels of type I, III and X collagen were enhanced in patients compared with controls. Production of type III and X collagen was higher in chondrocytes from patients with Kashin-Beck disease than in those from OA patients. CONCLUSIONS: Biochemical and morphological mechanisms underlying Kashin-Beck disease and OA include enhanced dedifferentiation and hypertrophy of chondrocytes, increased type I, III and X collagen levels, and suppressed type II collagen and aggrecan production compared with control samples.
Introduction
Kashin-Beck disease is a chronic and endemic osteochondropathy -involving degeneration and necrosis mainly in the growth plate and articular cartilage -which results in growth retardation, secondary osteoarthritis (OA) and disability in advanced stages. 1 -3 The disease is known to affect < 694 000 people worldwide, including 18 435 children < 13 years of age, but an estimated 104 million people in China are at risk. 4 The aetiology of Kashin-Beck disease is under debate, although three major environmental factors (endemic selenium ZQ Gao, X Guo, C Duan et al. Aggrecan and collagen in Kashin-Beck disease and osteoarthritis deficiency, serious cereal contamination by mycotoxin-producing fungi and high humic acid levels in drinking water) have been proposed as being closely related to this disorder since its discovery in 1849. 5 -7 Osteoarthritis is a leading cause of physical disability and impaired quality of life in industrialized nations, and is characterized by degradation and loss of articular cartilage, hypertrophic bone changes with osteophyte formation, subchondral bone remodelling, and (at the clinical stage disease) chronic inflammation of the synovial membrane. 8 Risk factors for OA include increasing age, susceptible genetic background, trauma, obesity, poor knee alignment and an imbalance of physiological processes, resulting in inflammatory cascades at the molecular level. 9 Pathological changes in patients with OA include articular cartilage breakdown, osteophyte formation, subchondral sclerosis and alterations of the synovium at morphological and biochemical levels. 10 Clinically, Kashin-Beck disease and OA have similar symptoms that are characterized by chronic pain, joint destruction, disability, depression and social isolation. Kashin-Beck disease displays similar pathological changes to OA, such as collagen destruction and aggrecan loss. 11 Little is known, however, about the similarities and differences between these diseases at the chondrocyte level. The present study aimed to obtain distinct expression profiles of aggrecan and collagen in chondrocytes isolated from samples of articular cartilage taken from adults with Kashin-Beck disease or OA, to help understand differences in the pathogenesis of these disorders. This study was approved by the Human Ethics Committee of the Medical College of Xi'an Jiaotong University, China. All patients provided either written or verbal informed consent. Written informed consent was obtained from the families of control subjects. Gibco BRL Life Technologies, Gaithersburg, MD, USA). Most samples were processed immediately; otherwise they were stored at 4°C for as short a time as possible before processing. After rinsing three times with 0.01 M phosphate buffered saline (PBS) (pH 7.2 -7.4), the chondrocytes were isolated from cartilage by sequential digestion using 0.2% trypsin for 1 h, 0.1% hyaluronidase for 1 h, and 0.25% type II collagenase for 8 h (1 ml of solution per 100 mg of tissue was used; all reagents were obtained from Gibco BRL Life Technologies). Released cells were placed in culture flasks in DMEM/F-12 medium supplemented with 10% fetal bovine serum (Minghai, Lanzhou, China), 100 IU/ml penicillin and 100 IU/ml streptomycin, and maintained at 37°C in a humidified atmosphere of 5% carbon dioxide. The medium was refreshed three times per week. After 4 -6 weeks of culture, cells were trypsinized and passaged. First-passage chondrocytes were used in all experiments in order to avoid chondrocyte dedifferentiation.
Patients and methods

STUDY POPULATION AND SAMPLE COLLECTION
ARTICULAR CHONDROCYTE CULTIVATION
MEASUREMENT OF AGGRECAN LEVELS
Aggrecan levels in chondrocytes were analysed by toluidine blue staining. Firstpassage chondrocytes were seeded on 8 × 8mm 2 poly-L-lysine-coated coverslips in 24well plates at a density of 1 × 10 4 cells/well and grown in DMEM/F-12 medium for 6 days, during which time the medium was replaced every other day. The cells were then fixed with 4% paraformaldehyde for 20 min and rinsed four times in 0.01 M PBS (pH 7.2 -7.4) for 5 min each time. The fixed tissue sections were stained using standard methods for 30 min with 0.04% (w/v) toluidine blue in 0.1 M sodium acetate buffer (pH 4.0), followed by incubation in 50% ethanol for 1 min and in 70% ethanol for 1 min. Finally, coverslips were sealed with neutral gum. The aggrecan synthesized by chondrocytes appeared as blue staining under standard light microscopy.
MEASUREMENT OF COLLAGEN EXPRESSION
Protein levels of type I, II, III and X collagen in chondrocytes from articular cartilage samples taken from each participant were analysed via immunocytochemical and immunofluorescent staining.
For immunocytochemical staining, chondrocytes cultured on coverslips were prepared as described for toluidine blue staining, fixed with 4% paraformaldehyde and rinsed with 0.01 M PBS (pH 7.2 -7.4). Immunocytochemistry was performed following the standard protocol of a streptavidin-biotin-peroxidase complex (SABC) kit (Sigma-Aldrich, St Louis, MO, USA). The cells were permeabilized with 0.2% Triton™ X-100 for 10 min. After endogenous peroxidase was blocked with 3% hydrogen peroxide for 10 min, the cells were incubated with 5% normal bovine serum in 0.01 M PBS (pH 7.2 -7.4) for 20 min at 37°C and washed with 0.01 M PBS (pH 7.2 -7.4). They were then incubated with primary rabbit antihuman antibodies to type I, II, III and X collagen (diluted 1:100; Sigma-Aldrich), or 0.01 M PBS (pH 7.2 -7.4) as a negative control, overnight at 4°C. The slides were then washed three times for 5 min in 0.01 M PBS (pH 7.2 -7.4) and incubated with biotinylated goat antirabbit immunoglobulin G secondary antibody (1:100 dilution; Sigma-Aldrich), at room temperature for 20 min. After again washing three times for 5 min with 0.01 M PBS (pH 7.2 -7.4), the slides were then incubated with SABC for 20 min at 37°C and ZQ Gao, X Guo, C Duan et al. Aggrecan and collagen in Kashin-Beck disease and osteoarthritis the peroxidase reaction was visualized with 0.3% diaminobenzidine buffer (Zymed Laboratories, San Francisco, CA, USA) containing 0.1% hydrogen peroxide. Finally, the cells were stained with haematoxylin, washed with distilled water, dehydrated through an ethanol series (80%, 95% and 99.9%) and xylene, and sealed with neutral gum. Samples were examined and photographed using a Zeiss Imager A1 fluorescence microscope (Zeiss, Gottingen, Germany).
Positive immunostaining appeared as brown-yellow granules, primarily in the cytoplasm.
For immunofluorescence staining, chondrocytes cultured on coverslips were fixed, permeabilized and incubated with 5% normal bovine serum, as described above. The cells were then incubated with primary antibodies against human recombinant type I, II, III and X collagen (diluted 1:100) overnight at 4°C, followed by rinsing with 0.01 M PBS (pH 7.2 -7.4). Cells were then incubated with a fluorescein isothiocyanate-labelled antirabbit antibody (Sigma-Aldrich) for 2 h at room temperature. After rinsing three times for 5 min with 0.01 M PBS (pH 7.2 -7.4), the slips were sealed with glycerol and the signal was detected using a Leica TCS SP2 Laser Scanning Confocal Microscope (Leica, Solms, Germany). Positive immunostaining appeared as green fluorescence in the cytoplasm.
Optical densities in immunocytochemical staining and fluorescence intensity in immunofluorescence staining were measured by Image-Pro™ Plus version 6.0 (Media Cybernetics, Bethesda, MD, USA). Six randomly chosen fields in each slide were counted at × 200 magnification and the means for optical density and fluorescence intensity were calculated.
STATISTICAL ANALYSES
All statistical analyses were carried out using the SPSS ® statistical package, version 17.0 (SPSS Inc., Chicago, IL, USA) for Windows ® . The mean ± SD values for optical density and fluorescence intensity were used for descriptive statistics. Differences among the groups were compared by one-way analysis of variance. A P-value of < 0.05 was considered to be statistically significant.
Results
Chondrocytes were obtained from articular cartilage samples from: patients with Kashin-Beck disease (three females and three males, aged 35 -47 years); patients with OA (three females and three males, aged 57 -73 years); control subjects (two females and four males, aged 27 -39 years).
Compared with normal chondrocytes from control subjects, chondrocytes from patients with arthritic disease contained lower levels of aggrecan ( Fig. 1) .
Type I collagen was not detected in chondrocytes from control subjects, but was detected in chondrocytes from patients with arthritic disease (Figs 2A -2C and 2M -2O;  Tables 1 and 2) ; levels were significantly higher in chondrocytes from patients with arthritic disease, compared with levels in chondrocytes from controls (P < 0.05). The mean level of type II collagen in chondrocytes from control subjects was significantly higher than that observed in chondrocytes from patients with arthritic disease (P < 0.05; Figs 
Discussion
Kashin-Beck disease and OA have very different pathological processes. Kashin-Beck disease is characterized by degeneration and necrosis in the deep zone of the growth plate and in articular cartilage 15 whereas, in OA, articular cartilage degeneration is the major pathological process. Compared with OA, which occurs mostly in older people, Kashin-Beck disease affects younger people. 15 As Kashin-Beck disease progresses, secondary OA occurs in most patients, together with extracellular matrix degradation, chondrocyte apoptosis and cartilage stripping. 16 Articular cartilage is a specialized avascular connective tissue that provides covering for the osseous components of diarthrodial joints; 8 it consists of chondrocytes and extracellular matrix, and serves as a load-bearing tissue that absorbs impact and is capable of sustaining shearing forces. The extracellular matrix of articular cartilage is a specialized connective tissue consisting of a hydrated proteoglycan gel that resists compression, reinforced by a network of collagen fibrils, 17 whereas chondrocytes are responsible for the homeostasis of articular cartilage, continually supplementing the matrix macromolecules lost during normal turnover. 18 Furthermore, the matrix can maintain the normal morphology and function of cartilage, and provide mechanical protection to chondrocytes.
Collagen accounts for about two-thirds of the dry weight of adult articular cartilage 19 and, in human articular cartilage, the major components are type II, IX and XI collagen. The greatest quantitative difference occurs with maturation from the exclusively fine fibrils of young articular cartilage (≥ 10%, collagen IX and XI; ≤ 80%, collagen II) to the thicker and more varied fibril diameters of mature cartilage (approximately 1% collagen IX; approximately 3% collagen XI; ≥ 90% collagen II). 20 Along with type II collagen, aggrecan forms a major structural component of articular cartilage; it contains three globular domains (G1, G2 and G3), which are involved in aggregation, hyaluronan binding, cell adhesion and chondrocyte apoptosis. 21 Aggrecan enables cartilage to resist compressive loads: high aggrecan concentrations provide the osmotic properties necessary for normal cartilage function, with proteoglycans combining with fluid to produce the swelling pressure that counters compressive loads on the cartilage. 22 Synthesis and degradation of collagen and aggrecan play important roles in maintaining normal cartilage structure and function. In OA, collagen II and aggrecan are degraded by protease and hyaluronidase. 23 As a person ages, the proteoglycan content may be reduced, which N) and OA (C, O) samples, with no difference between the two diseases. Type II collagen was present in all three groups, but stronger staining was seen in control (D, P) than in Kashin-Beck disease (E, Q) or OA (F, R) samples, with no difference between Kashin-Beck disease and OA samples. Type III collagen was present in all three groups, strongest in OA (I, U), and gradually decreasing in Kashin-Beck disease (H, T) and control samples (G, S). Type X collagen was present in all three groups, with the strongest staining in OA (L, X) compared with control (J, V) and Kashin-Beck disease (K, W) samples (original magnification × 200)
ZQ Gao, X Guo, C Duan et al. Aggrecan and collagen in Kashin-Beck disease and osteoarthritis reduces the amount of proteoglycan that combines with fluid, thereby leading to a decrease in cartilage resilience. Without the protective effects of proteoglycans, collagen fibres in the cartilage become susceptible to the processes of degradation and degeneration. 24 The present study showed varied collagen profiles in chondrocytes. Chondrocytes from Kashin-Beck disease and OA patients had lower levels of type II collagen, compared with levels observed in controls, indicating an impaired capacity of chondrocytes to synthesize and secrete type II collagen in Kashin-Beck disease and OA. Additionally, patients with Kashin-Beck disease had lower levels of type II collagen than patients with OA. The same situation was found with aggrecan, which was assessed by toluidine blue staining. As mentioned, in OA, type II collagen and aggrecan may degrade by the actions of protease, hyaluronidase and aggrecanases. At the same time, decreased collagen II and aggrecan synthesis may aggravate cartilage degeneration. In the present study, the significantly lower level of type II collagen observed in samples from patients with Kashin-Beck disease compared with controls is in accord with data reported by Wang et al. 3 Advances in detection technology (such as high-pressure cryofixation, freeze- 25 -27 Unlike type II collagen, which is localized in the same banded fibrils to retain its N-propeptide domain, type III collagen is polymerized and linked to type II collagen in human articular cartilage as a minor, but regular, component. 28, 29 Type III collagen was detected in all of the cartilage samples examined in the present study. Type III collagen levels were significantly higher in chondrocytes isolated from patients with Kashin-Beck disease and OA compared with control subjects, and were significantly higher in chondrocytes from OA patients compared with Kashin-Beck disease patients. It is tempting to speculate that, in response to matrix damage, type III collagen is made by chondrocytes in addition to type II collagen, and that this is akin to the wound-healing role of type III collagen in type I collagen-based tissues. 19 Type X collagen (a marker for chondrocyte hypertrophy) is confined to the hypertrophic zone of articular cartilage, and is thought to participate in endochondral ossification and in the degradation of cartilage in OA; it is often found in hypertrophic chondrocytes in the calcified zone of articular cartilage. 8 Type X collagen is also found in cartilage from patients with Kashin-Beck disease. 27, 30 The increased level of type X collagen found in chondrocytes from patients with OA or Kashin-Beck disease in the present study suggests that these chondrocytes may differentiate into a hypertrophic phenotype. Type X collagen may accumulate in apoptotic chondrocytes in OA. The increase of type X collagen in chondrocytes from OA patients may interfere with the normal interaction between collagens, resulting in disorganization of the normal scaffold structure in articular cartilage. 31 Type I collagen is the most abundant collagen found in the human body. It is widely accepted that type I collagen is absent in normal hyaline cartilage, and that fibrocartilage consists of type I collagen in addition to the normal (type II) collagen. Research has demonstrated that type I collagen can be detected in articular cartilage samples from patients with OA or Kashin-Beck disease. 27 Data from the current study have confirmed the presence of type I collagen in the chondrocytes of OA and Kashin-Beck disease. All these findings suggest a dedifferentiation status in chondrocytes cultured from OA and Kashin-Beck disease cartilage.
There were some limitations to the present study. First, chondrocytes in monolayer culture are prone to dedifferentiation, and antiaggrecan antibody staining may be more reliable than the toluidine blue staining used here. Secondly, the results may have been more convincing if polymerase chain reaction and Western blot analyses had been employed, together with immunocytochemical and immunofluorescence staining.
In summary, the present study found that chondrocytes, cultured from samples of knee cartilage taken from patients with Kashin-Beck disease or OA, present with dedifferentiation and hypertrophy. Type II collagen and aggrecan anabolic synthesis in the cells decrease greatly. Compared with chondrocytes cultured from cartilage samples taken from patients with OA, chondrocytes from Kashin-Beck disease samples undergo a greater decrease in anabolic synthesis.
